Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
New autoimmune diseases after cord blood transplantation: A retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation
Blood, Volume 121, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% ± 1% at 1 year and 6.6% ± 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs. © 2013 by The American Society of Hematology.
Authors & Co-Authors
Daikeler, Thomas D.
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Switzerland, Basel
Universitätsspital Basel
Labopin, Myriam
France, Paris
Hôpital Saint-antoine
Ruggeri, Annalisa
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Crotta, Alessandro
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Abinun, Mario A.
United Kingdom, Newcastle
Great North Children's Hospital
Hussein, Ayad Ahmed
Jordan, Amman
King Hussein Cancer Center
Carlson, Kristina S.
Sweden, Uppsala
Akademiska Sjukhuset
Cornillon, Jérôme
France, Saint-etienne
Institut de Cancérologie Lucien Neuwirth
Díez-Martín, José Luís
Spain, Madrid
Instituto de Investigación Sanitaria Gregorio Marañón
Gandemer, Virginie
France, Rennes
Hôpital de Rennes
Faraci, Maura
Italy, Genoa
Istituto Giannina Gaslini
Lindemans, Caroline A.(Caroline)
Netherlands, Utrecht
University Medical Center Utrecht
O'Meara, Anne M.W.
Ireland, Dublin
Our Lady's Hospital for Sick Children
Mialou, Valérie
France, Lyon
Institut D'hématologie et Oncologie Pédiatrique
Renard, Marleen M.
Belgium, Leuven
Ku Leuven– University Hospital Leuven
Sedláĉek, Petr
Czech Republic, Prague
Fakultní Nemocnice V Motole
Sirvent, Anne
France, Nice
Centre Hospitalier Universitaire de Nice, Hôpital L'archet
Socié, Gérard A.
France, Paris
Hôpital Saint-louis
Sorà, Federica
Italy, Rome
Università Cattolica Del Sacro Cuore, Campus Di Roma
Varotto, Stefania
Italy, Padua
Clinica Di Oncoematologia Pediatrica
Sanz, Jaime
Spain, Valencia
Hospital Infantil la fe
Voswinkel, Jan
France, Paris
Hôpital Saint-antoine
Vora, Ajay J.
United Kingdom, Sheffield
Sheffield Children's Hospital
Yeşilipek, Mehmet Akif M.
Turkey, Antalya
Akdeniz Üniversitesi
Herr, Andrée Laure
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Glückman, Éliane G.
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Farge, Dominique C.
France, Paris
Hôpital Saint-louis
Rocha, Vanderson G.
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
United Kingdom, Oxford
University of Oxford
Statistics
Citations: 72
Authors: 28
Affiliations: 23
Identifiers
Doi:
10.1182/blood-2012-07-445965
ISSN:
00064971
Study Design
Cohort Study